Duloxetine for the Treatment of Dysthymia
Trial ID or NCT#
Status
Purpose
The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of 60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients suffering from dysthymia. Dysthymia is chronic, mild depression characterized by feeling sad or low more days than not for more than 2 years.
Official Title
Duloxetine for the Treatment of Dysthymia
Eligibility Criteria
- :
- * Sign an informed consent form* 18 years of age or older* Females not pregnant or breastfeeding or planning pregnancy and using an acceptable form of contraception* Meet DSM-IV criteria for dysthymia* A screening IDS-C score of 17 or greater* No history of serious or unstable medical disorder* Not taking any significant concurrent medications* Not currently receiving psychotherapy
- - Suffering from DSM-IV defined* delirium, dementia, amnestic, or other cognitive disorders* mental disorders due to a general medical condition* factitious or somatoform disorders* mental retardation or developmental disabilities* substance or alcohol abuse within the last 3 months* depressive disorders with current suicidal risk* psychotic disorders including delusional disorder, somatic type* dissociative disorder* personality disorders sufficiently severe to interfere with study participation* History of DSM-IV defined bipolar I or II disorder* History of non-response of dysthymia to adequate antidepressant medication* History of major depression refractory to two adequate trials of antidepressants
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Nona Gamel
6507255180
View on